The U.S. Food and Drug Administration declined to approve Nabriva Therapeutics Plc’s antibiotic for complicated urinary tract infections, even as the United States grapples with the growing problem of antibiotic resistance.

Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.

The pharmaceutical industry should match its words with action on researching new antibiotics to address the threat posed by drug-resistant superbugs, a former UK government adviser said.

The U.S. FDA approved Aries Pharmaceuticals Inc.’s Aemcolo (rifamycin) for the treatment of adult patients with Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli.

The U.S. FDA approved Paratek Pharmaceuticals Inc.’s Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia and acute skin and skin structure infections.

SAB Therapeutics announced its first-in-human trial of new immunotherapy approach has shown efficacy in antibiotic-resistant bacteria based on a recent paper published online in Clinical Infectious Diseases.

Med Ad News’ first edition of the Pharma Leaders of Innovation special feature showcases two CEOs focusing outside the big pharma box and an agency tech leader.

Merck is globally committed to an antimicrobial stewardship encompassing surveillance, R&D, and health policy.

Researchers revealed the first U.S. case of a pathogen carrying a mutated strain of E. coli resistant to an antibiotic used as a final defense versus superbugs. As a result, there has been heightened concern that a post-antibiotic era will arrive earlier than predicted.

Latest Approval Expands Product Label in Canada and Further Strengthens Global Brand for Once-Daily, Dual Mechanism Antibiotic DUBLIN, IRELAND–(Marketwired – Jul 23, 2015) – Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance […]